In an adult with mild Crohn’s disease confined to the terminal ileum, how long should budesonide (Entocort) be given at 9 mg daily and what is the recommended tapering schedule?

Budesonide 9 mg Duration and Tapering for Mild Ileocecal Crohn's Disease

Treat with budesonide 9 mg once daily for 8 weeks, then taper over 1-2 weeks after achieving remission. 1, 2, 3

Treatment Duration

• Give budesonide 9 mg daily for exactly 8 weeks to induce remission in mild to moderate ileocecal Crohn's disease 1, 4, 2
• This 8-week duration is based on consistent evidence showing remission rates plateau around this timeframe, with approximately 51% of patients achieving remission (CDAI <150) compared to 20% with placebo 1, 5, 6
• The median time to symptomatic remission is 3-4 weeks, so you should see clear improvement by 4 weeks 4

Monitoring Response

• Evaluate for symptomatic response between 4-8 weeks to determine if therapy modification is needed 4, 3
• If the patient shows worsening or no improvement by 4 weeks, consider switching to systemic corticosteroids or escalating therapy rather than continuing budesonide 4
• Evidence of clinical benefit should be clearly apparent by 1-2 months; lack of response warrants intervention 4

Tapering Schedule

Once remission is achieved at 8 weeks, taper budesonide over 1-2 weeks rather than stopping abruptly 1, 3, 7

• The British Society of Gastroenterology specifically recommends this 1-2 week taper to avoid symptom recurrence 1, 3
• This is a relatively rapid taper compared to systemic steroids (which typically taper over 6-8 weeks), reflecting budesonide's lower systemic effects 1

Critical Cautions

• Do not use budesonide for maintenance therapy beyond the initial 8-week induction plus 1-2 week taper 4, 2, 3
• Multiple guidelines explicitly recommend against budesonide for maintenance of remission, as it is ineffective for this purpose and prolonged use causes significant adverse effects including adrenal suppression and bone loss 4, 2, 3, 7
• If the patient requires ongoing therapy after the taper, transition to appropriate maintenance agents (thiopurines, biologics, or small molecules) rather than continuing budesonide 2

Disease Severity Considerations

• Budesonide is only appropriate for mild to moderate disease (CDAI <300) 3
• In severe disease (CDAI >300), budesonide is inferior to systemic corticosteroids (prednisolone) and should not be used 1, 3
• Budesonide is effective only for disease limited to the ileum and/or ascending colon; it has no proven benefit for distal colonic inflammation 1, 2, 3